RECORD // Company

BridgeBio Pharma, Inc.

Formerly: BridgeBio Pharma LLC

Built 2026-11-21T07:08:08Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Matched by name only, not merged (9)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • BRIDGEBIO PHARMA, INC. · Ct business · same registered legal name as 'BridgeBio Pharma, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Bridgebio Pharma, Inc · Ctgov · same registered legal name as 'BridgeBio Pharma, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • BRIDGEBIO PHARMA INC · East licences · same registered legal name as 'BridgeBio Pharma, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • BRIDGEBIO PHARMA INC · East licences · same registered legal name as 'BridgeBio Pharma, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • BRIDGEBIO PHARMA LLC · East licences · same registered legal name as 'BridgeBio Pharma, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • BRIDGEBIO PHARMA, INC. · East licences · same registered legal name as 'BridgeBio Pharma, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • BRIDGEBIO PHARMA, INC. (lobbying via BRIDGEBIO PHARMA, INC.) · LDA lobbying · same registered legal name as 'BridgeBio Pharma, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • BRIDGEBIO PHARMA, INC. (lobbying via THORN RUN PARTNERS) · LDA lobbying · same registered legal name as 'BridgeBio Pharma, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • BRIDGEBIO PHARMA, INC. · USAspending · same registered legal name as 'BridgeBio Pharma, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

12 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-10-29 · accession 0001743881-26-000034

ItemValuePeriodFormFiledAccessionReport
Revenue$353,171,0003 months ended 2026-09-3010-Q2026-10-290001743881-26-0000342026-11-21 07:08 UTCReport an error
Net income (loss)$-56,710,0003 months ended 2026-09-3010-Q2026-10-290001743881-26-0000342026-11-21 07:08 UTCReport an error
Interest expense$13,255,0003 months ended 2026-09-3010-Q2026-10-290001743881-26-0000342026-11-21 07:08 UTCReport an error
Cash and cash equivalents$1,533,363,000at 2026-09-3010-Q2026-10-290001743881-26-0000342026-11-21 07:08 UTCReport an error
Contract liabilities, current$4,744,000at 2026-09-3010-Q2026-10-290001743881-26-0000342026-11-21 07:08 UTCReport an error
Contract liabilities, noncurrent$8,968,000at 2026-09-3010-Q2026-10-290001743881-26-0000342026-11-21 07:08 UTCReport an error
Debt due in the next 12 months$588,501,000at 2026-09-3010-Q2026-10-290001743881-26-0000342026-11-21 07:08 UTCReport an error
Debt due in year 2$31,626,000at 2026-09-3010-Q2026-10-290001743881-26-0000342026-11-21 07:08 UTCReport an error
Debt due in year 3$770,716,000at 2026-09-3010-Q2026-10-290001743881-26-0000342026-11-21 07:08 UTCReport an error
Debt due in year 4$14,807,000at 2026-09-3010-Q2026-10-290001743881-26-0000342026-11-21 07:08 UTCReport an error
Debt due in year 5$584,775,000at 2026-09-3010-Q2026-10-290001743881-26-0000342026-11-21 07:08 UTCReport an error
Debt due after year 5$639,629,000at 2026-09-3010-Q2026-10-290001743881-26-0000342026-11-21 07:08 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001743881
Ticker
BBIO
CUSIP
10806X102
Record ID
sx:sec:0001743881

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

30 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-20SEC EDGAR company profile2026-11-21 07:08 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-20SEC EDGAR company profile2026-11-21 07:08 UTCReport an error
State of incorporationDE2026-11-20SEC EDGAR company profile2026-11-21 07:08 UTCReport an error
Fiscal year end (MMDD)12312026-11-20SEC EDGAR company profile2026-11-21 07:08 UTCReport an error
Business address3160 PORTER DR., SUITE 250, PALO ALTO, CA, 943042026-11-20SEC EDGAR company profile2026-11-21 07:08 UTCReport an error
ExchangesNasdaq2026-11-20SEC EDGAR company profile2026-11-21 07:08 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$502,076,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 07:08 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-732,938,0002025-12-3110-K, XBRL ProfitLoss2026-11-21 07:08 UTCReport an error
Total assets (at 2025-12-31)$936,025,0002025-12-3110-K, XBRL Assets2026-11-21 07:08 UTCReport an error
Stockholders' equity (at 2025-12-31)$-2,086,610,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 07:08 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$570,119,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 07:08 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-445,910,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 07:08 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$1,097,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 07:08 UTCReport an error
Long-term debt (at 2025-12-31)$2,007,337,0002025-12-3110-K, XBRL LongTermDebt2026-11-21 07:08 UTCReport an error
Operating lease liabilities (at 2025-12-31)$10,003,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 07:08 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-10-29)On October 29, 2026, BridgeBio Pharma, Inc. (the “Company”) reported recent business updates and its financial results for the third quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act…2026-10-29SEC EDGAR 8-K 0001743881-26-000033 (text as filed, excerpt)2026-11-21 07:08 UTCReport an error
8-K Item 8.01 (filed 2026-10-13)Other Events. On October 6, 2026, BridgeBio Pharma, Inc. issued a press release titled “BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.2026-10-13SEC EDGAR 8-K 0001140361-26-039334 (text as filed, excerpt)2026-11-21 07:08 UTCReport an error
8-K Item 8.01 (filed 2026-08-31)Other Events. On August 31, 2026, BridgeBio Pharma, Inc. (the “Company”) issued a press release titled, “BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company expects its pricing commitment for its future medicines under its agreement with the U.S. government to exclude medicines approved exclusively for orphan indications. Forward-Looking Statements This Current Report on Form 8-K and certain of the materials filed herewith contain forward-looking statements. Such statements may…2026-08-31SEC EDGAR 8-K 0001140361-26-035055 (text as filed, excerpt)2026-11-21 07:08 UTCReport an error
8-K Item 1.01 (filed 2026-08-17)Entry into a Material Definitive Agreement. On August 13, 2026, BridgeBio Pharma, Inc. (the “Company”) and KKR Genetic Disorder L.P. (the “Selling Stockholder”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with William Blair & Company, L.L.C., Goldman Sachs & Co. LLC and KKR Capital Markets LLC, as the representatives of the several underwriters listed on Schedule I thereto (the “Underwriters”), related to an offering (the “Offering”) of 5,000,000 shares of common stock, par value $0.001 per share (“Shares”), of the Company by the Selling Stockholder at a price to the public of $78.00 per Share. The Company will not receive any of the proceeds from the sale of the…2026-08-17SEC EDGAR 8-K 0001140361-26-033282 (text as filed, excerpt)2026-11-21 07:08 UTCReport an error
8-K Item 8.01 (filed 2026-08-17)Other Events On August 13, 2026, the Company issued a press release announcing the launch of the Offering, and on August 14, 2026, the Company issued a press release announcing the pricing of the Offering. Copies of these press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and are each incorporated herein by reference.2026-08-17SEC EDGAR 8-K 0001140361-26-033282 (text as filed, excerpt)2026-11-21 07:08 UTCReport an error
Largest institutional holder #1 (13F as filed): Jupiter Topco LLC$1,050,761,5252026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:08 UTCReport an error
Largest institutional holder #2 (13F as filed): Kohlberg Kravis Roberts & Co. L.P.$987,677,1202026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:08 UTCReport an error
Largest institutional holder #3 (13F as filed): FARALLON CAPITAL MANAGEMENT, L.L.C.$800,143,3322026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:08 UTCReport an error
Largest institutional holder #4 (13F as filed): BlackRock, Inc.$766,187,3632026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:08 UTCReport an error
Largest institutional holder #5 (13F as filed): VIKING GLOBAL INVESTORS LP$741,017,8312026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:08 UTCReport an error
Largest institutional holder #6 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$588,315,5092026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:08 UTCReport an error
Largest institutional holder #7 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$570,272,6552026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:08 UTCReport an error
Largest institutional holder #8 (13F as filed): WELLINGTON MANAGEMENT GROUP LLP$395,408,6602026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:08 UTCReport an error
Largest institutional holder #9 (13F as filed): TWO SIGMA INVESTMENTS, LP$351,708,3392026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:08 UTCReport an error
Largest institutional holder #10 (13F as filed): Aisling Capital Management LP$341,834,2272026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 07:08 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.